HIV patients with high liver enzymes who lost visceral fat from tesamorelin kept their liver enzyme improvements for a full year even after stopping the drug, even though some fat came back.

For HIV patients with high liver enzymes taking a placebo, losing visceral fat didn't lead to better liver enzyme levels.

HIV patients with high liver enzymes who lost at least 8% of their visceral fat from the drug were 2.5 times more likely to have their ALT levels return to normal compared to those who didn't lose much fat.

HIV patients with high liver enzymes who lost at least 8% visceral fat after taking tesamorelin saw their ALT drop by about 9 units on average, while those without fat loss had a slight increase, showing a clear benefit from fat reduction.

Even after stopping tesamorelin and some fat coming back, the liver enzyme improvements stayed for a year in patients who initially lost visceral fat.

HIV patients with belly fat who took tesamorelin were more likely to lose at least 8% of their visceral fat than those who took a placebo.